Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: A retrospective analysis of the EWOG-MDS study group

Blood

Volumn 125, Issue 14, 2015, Pages 2311-2313

  Cseh, Annamaria ^a   Niemeyer, Charlotte M ^a,b   Yoshimi, Ayami ^a   Dworzak, Michael ^c   Hasle, Henrik ^d   Van Den Heuvel Eibrink, Marry M ^e   Locatelli, Franco ^f,g   Masetti, Riccardo ^h   Schmugge, Markus ⁱ   Groß Wieltsch, Ute ^j   Candás, Andrea ^k   Kulozik, Andreas E ^l   Olcay, Lale ^m   Suttorp, Meinolf ⁿ   Furlan, Ingrid ^o   Strahm, Brigitte ^a   Flotho, Christian ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^j OLGAHOSPITAL   (Germany)

^k Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

ⁿ UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^o UNIVERSITY HOSPITAL ULM   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CREATININE; ANTINEOPLASTIC ANTIMETABOLITE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CYTOPENIA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; INFANT; INFECTION; JUVENILE MYELOMONOCYTIC LEUKEMIA; LETTER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; VOMITING; CHROMOSOME ANALYSIS; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FOLLOW UP; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PRESCHOOL CHILD; PROGNOSIS; REMISSION;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CHILD; CHILD, PRESCHOOL; CYTOGENETIC ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 84926673191     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-619734     Document Type: Letter

References (10)

1. Santini V. Novel therapeutic strategies: hypomethylating agents and beyond. Hematology Am Soc Hematol Educ Program. 2012;2012:65-73.
2. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440.
3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
4. Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant. 2012;18(8):1211-1218.
5. Furlan I, Batz C, Flotho C, et al. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009;113(12):2867-2868.
6. Niemeyer CM, Loh ML, Cseh A, et al. Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. Haematologica. 2015;100(1):17-22.
7. Castleberry RP, Emanuel PD, Zuckerman KS, et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med. 1994;331(25):1680-1684.
8. Niemeyer CM, Arico M, Basso G, et al; European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood. 1997;89(10):3534-3543.
9. Castleberry RP, Loh ML, Jayaprakash N, et al. Phase II window study of the farnesyltransferase inhibitor R115777 (Zarnestra ®) in untreated juvenile myelomonocytic leukemia (JMML): a children's oncology group study [abstract]. Blood. 2005;106 (11). Abstract 2587.
10. Bergstraesser E, Hasle H, Rogge T, et al. Non-hematopoietic stemcell transplantation treatment of juvenilemyelomonocytic leukemia: a retrospective analysis and definition of response criteria. Pediatr Blood Cancer. 2007;49(5):629-633.